Lipoprotein subclasses-A changing landscape

Current Cardiovascular Risk Reports

Volumn 2, Issue 1, 2008, Pages 23-28

  Tsai, Michael Y ^a   Cao, Jing ^b  

^a Mayo Mail Code 609   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65949103098     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-008-0006-3     Document Type: Review

References (51)

1. American Heart Association: AHA Heart Disease and Stroke Statistics-2006. Available at http://www. americanheart. org/downloadable/heart/1136308648540Statupdate200 6. Accessed September 28, 2007.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143-3421.
3. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290: 898-904.
4. Lindgren FT, Elliott HA, Gofman JW: The ultracentrifugal characterization and isolation of human blood lipids and lipoproteins, with applications to the study of atherosclerosis. J Phys Colloid Chem 1951, 55: 80-93.
5. Blanche PJ, Gong EL, Forte TM, Nichols AV: Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981, 665: 408-419.
6. Li Z, McNamara JR, Ordovas JM, Schaefer EJ: Analysis of high density lipoproteins by a modified gradient gel electrophoresis method. J Lipid Res 1994, 35: 1698-1711.
7. Cheung MC, Albers JJ: Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem 1984, 259: 12201-12209.
8. Asztalos BF, Sloop CH, Wong L, Roheim PS: Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993, 1169: 291-300.
9. Hopkins GJ, Barter PJ: Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 1986, 27: 1265-1277.
10. Tailleux A, Fruchart JC: HDL heterogeneity and atherosclerosis. Crit Rev Clin Lab Sci 1996, 33: 163-201.
11. Cheung MC, Brown BG, Wolf AC, Albers JJ: Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991, 32: 383-394.
12. Asztalos BF, Horvath KV, McNamara JR, et al.: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002, 164: 361-369.
13. Johansson J, Carlson LA, Landou C, Hamsten A: High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991, 11: 174-182.
14. Asztalos BF, Collins D, Cupples LA, et al.: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005, 25: 2185-2191.
15. Lindgren FT, Jensen LC, Wills RD, Freeman NK: Flotation rates, molecular weights and hydrated densities of the low-density lipoproteins. Lipids 1969, 4: 337-344.
16. Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low density lipoproteinsin normal humans. J Lipid Res 1982, 23: 97-104.
17. McNamara JR, Campos H, Ordovas JM, et al.: Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study. Arteriosclerosis 1987, 7: 483-490.
18. Austin MA, Breslow JL, Hennekens CH, et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260: 1917-1921.
19. Stampfer MJ, Krauss RM, Ma J, et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276: 882-888.
20. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276: 875-881.
21. Mykkanen L, Kuusisto J, Haffner SM, et al.: LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 1999, 19: 2742-2748.
22. Austin MA, Rodriguez BL, McKnight B, et al.: Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000, 86: 412-416.
23. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95: 69-75.
24. Griffin BA, Freeman DJ, Tait GW, et al.: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994, 106: 241-253.
25. Skoglund-Andersson C, Tang R, Bond MG, et al.: LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol 1999, 19: 2422-2430.
26. Williams PT, Superko HR, Haskell WL, et al.: Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003, 23: 314-321.
27. Superko HR, Williams PT, Boggess C: Small LDL IVb predicts mortality independent of other lipoprotein measurements. Presented at the 2004 Scientific Sessions of the American Heart Association. New Orleans; November 7-10, 2004. Presentation 3782.
28. Yuan J, Tsai MY, Hunninghake DB: Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994, 110: 1-11.
29. Kamigaki AS, Siscovick DS, Schwartz SM, et al.: Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol 2001, 153: 939-945.
30. Otvos JD, Jeyarajah EJ, Bennett DW, et al.: Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38: 1632-1638.
31. Jeyarajah EJ, Cromwell WC, Otvos JD: Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26: 847-870.
32. Otvos JD, Collins D, Freedman DS, et al.: LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2006, 113: 1556-1563.
33. Rosenson RS, Freedman DS, Otvos JD: Relations of lipoprotein subclass levels and LDL size to progression of coronary artery disease in the PLAC I trial. Am J Cardiol 2002, 90: 89-94.
34. Mora S, Szklo M, Otvos JD, et al.: LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192: 211-217.
35. Kuller L, Arnold A, Tracy R, et al.: NMR spectroscopy of lipoproteins and risk of CHD in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2002, 22: 1175-1180.
36. Kathiresan S, Otvos JD, Sullivan LM, et al.: Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113: 20-29.
37. El Harchaoui K, van der Steeg WA, Stroes ES, et al.: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49: 547-553.
38. Blake GJ, Otvos JD, Rifai N, Ridker PM: LDL particle concentration and size as determined by NMR spectroscopy as predictors of cardiovascular disease in women. Circulation 2002, 106: 1930-1937.
39. Cromwell WC, Otvos JD: Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004, 6: 381-387.
40. Sniderman AD, Marcovina SM: Apolipoprotein A1 and B. Clin Lab Med 2006, 26: 733-750.
41. Ensign W, Hill N, Heward CB: Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006, 52: 1722-1727.
42. Warnick GR, McNamara JR, Boggess CN, et al.: Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006, 26: 803-846.
43. Guerin M, Bruckert E, Dolphin PJ, et al.: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16: 763-772.
44. Ridker PM, Rifai N, Cook NR, et al.: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294: 326-333.
45. Kastelein JJ, van Leuven SI, Burgess L, et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356: 1620-1630.
46. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al.: Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000, 101: 1907-1912.
47. Arakawa R, Tamehiro N, Nishimaki-Mogami T, et al.: Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005, 25: 1193-1197.
48. Ansell BJ, Watson KE, Fogelman AM, et al.: High-density lipoprotein function recent advances. J Am Coll Cardiol 2005, 46: 1792-1798.
49. US Food and Drug Administration, Center for Devices and Radiological Health: CDRH Advisory Committees. Available at: http://www. accessdata. fda. gov/scripts/cdrh/cfdocs/cfAdvisory/details. cfm?mtg=613. accessed November 15, 2007.
50. Vega GL, Ma PT, Cater NB, et al.: Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003, 91: 956-960.
51. Taylor AJ, Sullenberger LE, Lee HJ, et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110: 3512-3517.